Chemotherapy in alveolar soft part sarcomas - What do we know?

By Reichardt P.   Lindner T.   Pink D.   Thuss-Patience P.C.   Kretzschmar A.   Dorken B.  

European Journal of Cancer, Vol. 39, Iss. 11, 2003-07 ,pp. : 1511-1516

Elsevier

Access to resources Recommend Favorite

Management of brain metastases from germ cell tumors: do we know what we are doing?

By Raj Sanjay   Parkinson Christine   Williams Michael   Mazhar Danish  

Future Oncology, Vol. 4, Iss. 1, 2008-02 ,pp. : 1-4

Future Medicine

Access to resources Recommend Favorite

Biochemical approach to the detection and monitoring of metastatic bone disease: What do we know and what questions need answers?

By Tankó László   Karsdal Morten   Christiansen Claus   Leeming Diana  

Cancer and Metastasis Reviews, Vol. 25, Iss. 4, 2006-12 ,pp. : 659-668

Springer Publishing Company

Access to resources Recommend Favorite

Central venous catheter-related thrombosis in cancer patients: what we know and what we need to know

By Tassinari Davide  

Supportive Care in Cancer, Vol. 16, Iss. 3, 2008-03 ,pp. : 311-312

Springer Publishing Company

Access to resources Recommend Favorite

Impact of Scheduling on Toxicity and Clinical Efficacy of Doxorubicin: What Do We Know in the Mid-Nineties?

By Bielack S.S.   Erttmann R.   Kempf-Bielack B.   Winkler K.  

European Journal of Cancer, Vol. 32, Iss. 10, 1996-09 ,pp. : 1652-1660

Elsevier

Access to resources Recommend Favorite